Get the Stockscreener App
2.50
0.79%
-0.02
After Hours:
2.50
Allogene Therapeutics Inc stock is traded at $2.50, with a volume of 2.24M.
It is down -0.79% in the last 24 hours and up +2.46% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$2.52
Open:
$2.53
24h Volume:
2.24M
Relative Volume:
1.05
Market Cap:
$528.37M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-1.0204
EPS:
-2.45
Net Cash Flow:
$-239.25M
1W Performance:
+21.95%
1M Performance:
+2.46%
6M Performance:
-0.79%
1Y Performance:
-1.57%
1-Day Range:
$2.48
$2.6191
1-Week Range:
$2.005
$2.77
52-Week Range:
$1.99
$5.775
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.50 | 528.37M | 95,000 | -327.27M | -239.25M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com
Allogene stock touches 52-week low at $2 amid market challenges - Investing.com
Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN
ALLOAllogene Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Allogene Therapeutics Announces Participation in December Investor Conferences - The Manila Times
Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - The Manila Times
Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire
Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan
Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat
Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia
Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™
Allogene halts enrollment in leukemia trial - Investing.com
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace
Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat
Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India
Allogene Therapeutics Q3 2024 Earnings Preview - MSN
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Allogene Therapeutics reports on CAR T therapy progress - Investing.com
Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright - MarketBeat
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlight - GuruFocus.com
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... - Yahoo Finance
Allogene Therapeutics: Q3 Earnings Snapshot - The Washington Post
Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire
Allogene Therapeutics Announces Positive Phase 1 Data - GlobeNewswire
Allogene's Cancer Drug Shows 50% Response Rate in Phase 1 Trial, Earns FDA Designation | ALLO Stock News - StockTitan
Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Allogene Therapeutics to Present New Data Demonstrating the - GlobeNewswire
Allogene's ALLO-316 Cancer Therapy Shows Promise: Key Trial Data Coming at Major Symposiums | ALLO Stock News - StockTitan
Vanguard Group Inc's Strategic Acquisition in Allogene Therapeutics Inc - GuruFocus.com
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.3%Still a Buy? - MarketBeat
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Allogene Therapeutics Announces Participation in November Investor Conferences - StockTitan
Allogene Therapeutics’ (ALLO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Allogene shares hold buy rating as FDA grants RMAT to ALLO-316 - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - The Manila Times
FDA grants RMAT status to Allogene's kidney cancer therapy By Investing.com - Investing.com South Africa
FDA grants RMAT status to Allogene's kidney cancer therapy - Investing.com
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) - The Manila Times
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):